Annexon, Inc.

64 articles about Annexon, Inc.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - May 16, 2023

  5/16/2023

  Annexon, Inc. announced that it has granted equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

  5/8/2023

  Annexon, Inc. reported first quarter 2023 financial results and highlighted recent progress across its portfolio of complement therapies.

• Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

  4/11/2023

  Annexon, Inc. announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 1:30 p.m. ET.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - February 16, 2023

  2/16/2023

  Annexon, Inc. announced that it has granted equity inducement awards to four new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Jan 17, 2023

  1/17/2023

  Annexon, Inc. announced that it has granted an equity inducement award to Dean “Rick” Artis, Ph.D., chief scientific officer, under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

  1/8/2023

  Annexon, Inc. reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.

• Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - November 17, 2022

  11/17/2022

  Annexon, Inc. announced that it has granted an equity inducement award to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023

  11/3/2022

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, reported third quarter 2022 financial results.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - October 18, 2022

  10/18/2022

  Annexon, Inc. announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - September 16, 2022

  9/16/2022

  Annexon, Inc. announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Aug 17, 2022

  8/17/2022

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• 

  Can AAV Gene Therapy Transcend Challenges in the Huntington's Space?

  7/13/2022

  uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company's president of R&D, Dr. Ricardo Dolmetsch.
• 

  Pliant and Annexon Seek and Secure Funds for Pulmonary Fibrosis, Autoimmune Treatments

  7/12/2022

  Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.

• Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

  7/11/2022

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced the closing of its private placement, resulting in gross proceeds of approximately $130 million, before deducting placement agent fees and other expenses.

• 

  Annexon Engages the Target, Sees Stabilization in Phase II Huntington's Trial

  6/8/2022

  Annexon released final data from an open-label phase II clinical trial, showing that its drug candidate ANX005 safely stabilized disease progression in patients with Huntington’s disease.

• Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

  6/7/2022

  Annexon, Inc. announced promising, final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease.

• Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

  6/2/2022

  Annexon, Inc. announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.

• Annexon Biosciences to Participate in Upcoming May 2022 Investor Conferences

  5/5/2022

  Annexon, Inc. announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:

• 

  Octant Scores $80M in Series B Funds, Partnership with BMS

  4/21/2022

  Octant announced an $80 million Series B financing round, a Deep Mutual Scanning (DMS) biopharma partnership with Bristol Myers Squibb and key appointments to its leadership.
• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.